secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2026-06-15T12:01:32+00:00
Accession:  0001636282-26-000083
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre reports positive Phase 2 topline data for SPY002 in ulcerative colitis; met primary endpoint
--------------------------------------------------------------------------------

- SPY002 achieved primary endpoint: 10.7-point RHI reduction (p<0.0001) at 12 weeks.
- Clinical remission rate 33%, endoscopic improvement rate 42%, modified Mayo Score change -3.7.
- Well tolerated; safety profile consistent with TL1A class; no drug-related SAEs.
- Two SAEs (UC exacerbation, heart failure) deemed not drug-related; no deaths.
- Company on track to report SPY003 Part A data in Q3 2026 and enrolling Part B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628226000083/0001636282-26-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628226000083/syre-20260615.htm
  HTML page:      https://secwatch.observer/filing/0001636282-26-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer